Davis Rea LTD. Buys New Shares in Intuitive Surgical, Inc. $ISRG

Davis Rea LTD. purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,474 shares of the medical equipment provider’s stock, valued at approximately $6,920,000. Intuitive Surgical makes up 1.7% of Davis Rea LTD.’s holdings, making the stock its 19th biggest position.

Several other institutional investors have also recently made changes to their positions in ISRG. Tobam grew its stake in shares of Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 40 shares during the period. Kilter Group LLC bought a new stake in Intuitive Surgical during the 2nd quarter worth approximately $27,000. Princeton Global Asset Management LLC purchased a new position in Intuitive Surgical during the second quarter valued at approximately $30,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Intuitive Surgical by 84.2% in the second quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 32 shares during the period. Finally, First Command Advisory Services Inc. boosted its position in shares of Intuitive Surgical by 3,750.0% in the second quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 75 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ISRG shares. UBS Group restated a “neutral” rating on shares of Intuitive Surgical in a research report on Thursday. Truist Financial raised their price target on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Citigroup downgraded Intuitive Surgical from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $650.00 to $635.00 in a research report on Thursday, December 11th. Wells Fargo & Company upped their price objective on Intuitive Surgical from $600.00 to $654.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Mizuho set a $575.00 target price on Intuitive Surgical in a research note on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $622.17.

Intuitive Surgical Trading Down 1.0%

Shares of Intuitive Surgical stock opened at $541.34 on Friday. The stock has a 50 day moving average of $566.82 and a 200 day moving average of $512.30. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The firm has a market cap of $194.06 billion, a PE ratio of 71.61, a PEG ratio of 4.44 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the firm earned $1.84 EPS. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 results beat expectations: procedure volume, system placements and revenue all grew, and management raised full‑year revenue guidance vs prior consensus—evidence of demand strength. Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Industry analysts reiterated buy/supportive views: Bernstein kept a Buy rating and William Blair reiterated bullish sentiment citing DV5 adoption and pipeline, which supports longer‑term growth expectations. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Company commentary and industry coverage note da Vinci systems “exceeded expectations” in procedures and placements, underlining the platform’s commercial traction. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Neutral Sentiment: IS‑001 Phase 3 update (imaging‑driven safety product) is in progress — relevant for the pipeline but uncertain timing/impact on revenue; watch trial readouts. IS-001 Phase 3 Update
• Neutral Sentiment: da Vinci 5 international rollout is expanding but faces pricing, budget and reimbursement hurdles overseas — a mixed catalyst: growth potential but adoption risk outside the U.S. da Vinci 5 Expands Globally
• Negative Sentiment: Management set a softer 2026 outlook and lowered its expected da Vinci growth cadence for the year, which overshadowed the Q4 beat and prompted the pullback as investors re‑price growth expectations. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction focused on a missed/tepid 2026 da Vinci growth projection despite solid quarterly results — traders viewed this as evidence of near‑term deceleration. da Vinci Growth Projection Misses Expectations
• Negative Sentiment: Commentary across outlets: “shares fell despite beating Q4” highlights investor sensitivity to forward guidance and valuation (high PE multiple); this sentiment amplified the decline. Why Intuitive Surgical Stock Is Falling Today

Insider Buying and Selling at Intuitive Surgical

In other news, CEO David J. Rosa sold 24,500 shares of the company’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $547.55, for a total transaction of $13,414,975.00. Following the sale, the chief executive officer directly owned 234,256 shares in the company, valued at approximately $128,266,872.80. This represents a 9.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary S. Guthart sold 28,800 shares of the stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $547.56, for a total transaction of $15,769,728.00. Following the completion of the transaction, the insider directly owned 27,027 shares of the company’s stock, valued at approximately $14,798,904.12. The trade was a 51.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 114,007 shares of company stock valued at $63,533,844 over the last ninety days. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.